Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly

An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies

Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark

The IASLC Fight Against Lung Cancer in Peru and Latin America

Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement

Q&A with Dr. D. Ross Camidge

Keeping It Personal: CMS-Proposed Coverage Restrictions for NGS Challenge Innovation in Personalized Care

Q&A with TMB Expert Dr. Solange Peters

Q&A with the New IASLC President

An American Perspective on the European Lung Cancer Screening Implementation Plans